This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Tositumomab
From Proteopedia
(Difference between revisions)
| Line 20: | Line 20: | ||
! 167000 | ! 167000 | ||
! 205800 | ! 205800 | ||
| - | ! | + | ! 67000 |
|- | |- | ||
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ||
| Line 32: | Line 32: | ||
! 68 | ! 68 | ||
! 206 | ! 206 | ||
| - | ! | + | ! 108 |
|- | |- | ||
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
| Line 38: | Line 38: | ||
! 32939000 | ! 32939000 | ||
! Rituximab | ! Rituximab | ||
| - | ! | + | ! 17000 |
|- | |- | ||
! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) | ! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) | ||
Current revision
Pharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics [1] | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | 7.6 | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | 167000 | 205800 | 67000 |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | 64.8 | 68 | 206 | 108 |
| AUC (ng/ml/hr) | Tositumomab | 32939000 | Rituximab | 17000 |
| Clearance (L/h) | .078 | .017 | .009 | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage | Tositumomab | 500 mg (4th Infusion) | 325 mg/m2 (4th Infusion) | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
